Daniel Joyce, MD
Daniel Joyce, MD, is an Assistant Professor in the Department of Urology at Vanderbilt University Medical Center, specializing in the treatment of kidney Cancer, testis Cancer, bladder Cancer, and prostate cancer.
Articles by Daniel Joyce, MD
Drs. Joyce and Jani look toward the future of liquid biopsy in RCC care and how new technology, like AI, will play a role.
Drs. Joyce and Jani discuss practical clinical cases of using liquid biopsy to manage patients in different RCC settings.
Drs. Joyce and Jani talk about the technique of liquid biopsy and its role as a diagnostic tool in RCC.
Drs. Chang and Joyce consider the role that N-803 now plays within the treatment paradigm for BCG-unresponsive bladder CIS.
Drs. Chang, Joyce take a look at QUILT-3.032, including complete responses to N-803 plus BCG in BCG-unresponsive bladder CIS.
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Xu and Joyce break down the evaluation of circulating KIM-1 as a prognostic and predictive biomarker in advanced RCC.
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
Dr. Simpa Salami's research into a 15-gene prognostic signature for predicting ccRCC risk is discussed in this interview.
Drs. Xu and Joyce explain the rationale behind recent research on plasma KIM-1, its significance as a biomarker, and more.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.